Genomtec (DB:4VI) - Stock Price, News & Analysis

4VI Stock Overview

Researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. More details

4VI fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings have grown 1.1% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue (PLN2K)

Shareholders have been diluted in the past year

Does not have a meaningful market cap (€99M)

Genomtec S.A. Competitors

4SC

DB:VSC

€55.6m

Medigene

XTRA:MDG1

€23.7m

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€1.5m

Price History & Performance

Summary of all time highs, changes and price drops for Genomtec
Historical stock prices
Current Share Price	zł1.52
52 Week High	zł3.35
52 Week Low	zł1.45
Beta	0.21
11 Month Change	-13.65%
3 Month Change	-19.00%
1 Year Change	-30.68%
33 Year Change	-25.52%
5 Year Change	n/a
Change since IPO	-41.50%

Recent updates

Shareholder Returns

	4VI	DE Biotechs	DE Market
7D	-1.4%	0.8%	-1.3%
1Y	-30.7%	-17.5%	7.4%

Return vs Industry: 4VI underperformed the German Biotechs industry which returned -16.7% over the past year.

Return vs Market: 4VI underperformed the German Market which returned 7.1% over the past year.

Price Volatility

Is 4VI's price volatile compared to industry and market?
4VI volatility
4VI Average Weekly Movement	5.9%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 4VI has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 4VI's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2016	17	Miron Tokarski	www.genomtec.com

Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus.

Genomtec S.A. Fundamentals Summary

How do Genomtec's earnings and revenue compare to its market cap?
4VI fundamental statistics
Market cap	€22.79m
Earnings (TTM)	-€2.53m
Revenue (TTM)	€460.34

Over9,999x

P/S Ratio

-9.0x

P/E Ratio

Is 4VI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4VI income statement (TTM)
Revenue	zł2.00k
Cost of Revenue	zł2.29m
Gross Profit	-zł2.28m
Other Expenses	zł8.71m
Earnings	-zł11.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 29, 2024

Earnings per share (EPS)	-0.83
Gross Margin	-114,200.00%
Net Profit Margin	-549,850.00%
Debt/Equity Ratio	3.2%

How did 4VI perform over the long term?

See historical performance and comparison

Genomtec DB:4VI Stock Report